These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 18219317)

  • 21. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas.
    Cuevas Y; Hernández-Alcoceba R; Aragones J; Naranjo-Suárez S; Castellanos MC; Esteban MA; Martín-Puig S; Landazuri MO; del Peso L
    Cancer Res; 2003 Oct; 63(20):6877-84. PubMed ID: 14583486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. pVHL modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development.
    Stickle NH; Chung J; Klco JM; Hill RP; Kaelin WG; Ohh M
    Mol Cell Biol; 2004 Apr; 24(8):3251-61. PubMed ID: 15060148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
    Zhou L; Yang H
    PLoS One; 2011; 6(9):e23936. PubMed ID: 21949687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI; Jewett MA; Ohh M
    Am J Physiol Renal Physiol; 2004 Jul; 287(1):F1-6. PubMed ID: 15180922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K; Cartwright E; Freund S; Bycroft M; Buchberger A
    J Biol Chem; 2009 Apr; 284(16):10514-22. PubMed ID: 19228690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Von-Hippel-Lindau (VHL) protein function by initiation and progression of renal cancer].
    Moch H
    Pathologe; 2008 Nov; 29 Suppl 2():149-52. PubMed ID: 18751708
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma.
    Kaelin WG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):680s-684s. PubMed ID: 17255293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
    Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL.
    Li M; Kim WY
    J Cell Mol Med; 2011 Feb; 15(2):187-95. PubMed ID: 21155973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The von Hippel-Lindau tumor suppressor gene.
    Kondo K; Kaelin WG
    Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Von Hippel-Lindau disease.
    Kaelin WG
    Annu Rev Pathol; 2007; 2():145-73. PubMed ID: 18039096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
    Zhang YT; Chen N; Zeng H; Zhou Q
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
    [No Abstract]   [Full Text] [Related]  

  • 34. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.
    Zimmer M; Doucette D; Siddiqui N; Iliopoulos O
    Mol Cancer Res; 2004 Feb; 2(2):89-95. PubMed ID: 14985465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. USP9X destabilizes pVHL and promotes cell proliferation.
    Zhang C; Peng Z; Zhu M; Wang P; Du X; Li X; Liu Y; Jin Y; McNutt MA; Yin Y
    Oncotarget; 2016 Sep; 7(37):60519-60534. PubMed ID: 27517496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
    Miller F; Kentsis A; Osman R; Pan ZQ
    J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.
    Sorrell AD; Lee S; Stolle C; Ellenhorn J; Grix A; Kaelin WG; Weitzel JN
    Clin Genet; 2011 Jun; 79(6):539-45. PubMed ID: 20560986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of drugs targeting hypoxia-inducible factor against tumor cells with VHL mutation: Story of 127 years.
    Takamori H; Yamasaki T; Kitadai R; Minamishima YA; Nakamura E
    Cancer Sci; 2023 Apr; 114(4):1208-1217. PubMed ID: 36650918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Von Hippel-Lindau syndrome: molecular mechanisms of the disease.
    Calzada MJ
    Clin Transl Oncol; 2010 Mar; 12(3):160-5. PubMed ID: 20231120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.
    Maxwell PH; Wiesener MS; Chang GW; Clifford SC; Vaux EC; Cockman ME; Wykoff CC; Pugh CW; Maher ER; Ratcliffe PJ
    Nature; 1999 May; 399(6733):271-5. PubMed ID: 10353251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.